NEWS & INDUSTRY UPDATES
As research continues & more data becomes available, we will deepen our understanding of the impact that psychedelics have in reducing the economic and health burden of mental health disorders.
ATMA Journey Centers Secures Supply Contract With Havn Life Sciences For GMP Grade Naturally-Derived Psilocybin On The Heels Of New Section 56 Exemptions
Supply agreement provides ATMA with a legal and reliable source of psilocybin to fuel its growth and expansion as a leader in therapy, experiential therapist training and facilitator of clinical trials
ATMA Journey Centers Announces Two New Section 56 Exemptions Granted By Health Canada, Responding To Increasing Demand For Psychedelic Medicine
Patients become part of a growing movement in Canada to increase access and awareness of psychedelic-assisted therapy to help palliative patients deal with mental distress and anxiety
Canada’s First Psychedelic Training Program for Mental Health Professionals Concludes and is Deemed a Huge Success
Innovative training program provides therapists across the country with access to leading-edge training on psychedelic medicine and assisted therapy with Continuing Education Credits